The good publication practice for pharmaceutical companies (GPP) guidelines were first published in 2003, then revised in 2009 (GPP2) and most recently in 2015 (GPP3). The latest version reflects the changes that have occurred in legislation concerning dissemination of data from clinical trials, mainly focussed on the pharmaceutical industry. These guidelines are intended to serve as a basis for publication professionals to establish transparent and ethical working practices within the pharmaceutical industry. The need for such guidance and the main differences in the latest version are introduced.